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Abstract 
Guillain-Barré syndrome (GBS) is an acute, autoimmune inflammatory disorder of peripheral 
nervous system characterized by a severe functional motor weakness. Treatment with 
intravenous immunoglobulin (IVIg) is one of the approved and preferred therapeutic 
strategies for GBS. However, the mechanisms underlying the therapeutic benefit with IVIg in 
GBS are not completely understood. In the present study, we observed that GBS patients 
have increased frequencies of Th1 and Th17 cells, but reduced number of Foxp3+ regulatory 
T cells (Treg cells) with defective functions. We show that IVIg treatment in GBS patients 
results in a marked reduction in the frequency of Th1 and Th17 cells with a concomitant 
expansion of Treg cells. Importantly, IVIg-expanded Treg cells exhibited an increased T cell 
suppressive function. Together our results demonstrate that therapeutic benefit of IVIg in 
GBS patients implicates the reciprocal regulation of Th1/Th17 and Treg cells. 
Key words 
Intravenous immunoglobulin, IVIg, Guillain-barre syndrome, Th1 cells, Th17 cells, 
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Introduction 
Intravenous immunoglobulin (IVIg) is a therapeutic preparation, mainly of polyspecific IgG, 
obtained from the pooled plasma of several thousand healthy donors [1-3]. Although first 
used for immunoglobulin substitution in patients with immunodeficiencies, IVIg is now 
increasingly used in the treatment of several autoimmune and systemic inflammatory diseases 
[1, 4-7]. The therapeutic efficacy of IVIg in immunodeficiency as well as immune-mediated 
diseases is accomplished by bringing about homeostasis of dysregulated immune system, in 
addition to immunoglobulin replacement [8-14]. Although several mutually non-exclusive 
mechanisms are proposed [15-19], the cellular and molecular events underlying the 
therapeutic benefits of IVIg, particularly in autoimmune diseases, are still less understood.    
Guillain-Barré syndrome (GBS) is an autoimmune, acute, inflammatory polyneuropathy of 
the peripheral nervous system. Despite an incidence rate of 0.6-4 per 100 000 per year 
throughout the world, GBS is considered to be a frequent cause of neuromuscular paralysis at 
all ages [20-22]. There are several subtypes of GBS described. The axonal subtypes, such as 
acute motor axonal neuropathy (AMAN), and acute motor and sensory axonal neuropathy 
(AMSAN) are relatively rare and are predominantly caused by antibodies to gangliosides [20, 
21]. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP) with predominant 
motor deficit is the most common subtype of GBS and resembles experimental autoimmune 
neuritis (EAN), which is mainly caused by T cells reactive to myelin proteins P0, P2, and 
PMP22 [20]. The role of T-cell-mediated immunity in AIDP was unclear until recent studies 
revealed the increased frequency of Th1 as well as Th17 cells in the peripheral blood, and 
elevated levels of T-cell effector cytokines such as IFN-γ, IL-17 and IL-22 in the 
cerebrospinal fluid of GBS patients [23-26]. These findings are consistent with the observed 
pathogenic role of Th1 and Th17 cells in several autoimmune and inflammatory disease [27-
34] Furthermore, CD4+Foxp3+ regulatory T (Treg) cells, which play critical role in the 
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maintenance of immune tolerance and prevention of autoimmunity [35-44] are significantly 
reduced in GBS patients as well as EAN models [25, 45, 46]. Therefore, similar to other 
autoimmune inflammatory disease, therapeutic molecules that target both Treg cells and 
effector T (Teff) cells (Th1 and Th17 cells) are being investigated for the treatment of GBS 
[24, 25].  
In this context, IVIg is a proven effective treatment for GBS and is currently preferred over 
plasma exchange due to its similar efficacy, easier administration and more favourable side-
effect profile [21, 47-50]. Of particular interest, IVIg is found to induce expansion of Treg 
cells in vitro as well as in autoimmune patients and experimental animal models [51-62]. 
Furthermore, in addition to Th1 cells, recent evidences from experimental animal models as 
well as in vitro studies have shown that IVIg inhibits the development of Th17 cells and 
production of their effector molecules, including IL-17, IL-22 and GM-CSF [30, 63-67]. 
However, it is not clear whether the beneficial effects IVIg therapy in GBS and other 
autoimmune and inflammatory diseases is associated with the inhibition of Th1 and Th17 
cells. 
Since the up-regulation of Treg cells and inhibition of Teff cells is important for the alleviation 
of autoimmune inflammatory conditions [28, 68], and IVIg treatment of autoimmune patients 
is associated with restoration of immune homeostasis, we hypothesised that the beneficial 
effect of IVIg therapy in GBS patients is associated with reciprocal regulation of  Treg cells 
and effector Th1 and Th17 cell populations. 
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Materials and methods 
Patients and healthy donors 
This is a multicentric study, consisting of 5 GBS patients and 4 healthy donors. Blood 
samples of control group were obtained from 4 healthy donors from Hôpital Hôtel Dieu, 
Etablissement Français du Sang, Paris, France with an appropriate ethical approval 
(N°12/EFS/079). Patients with GBS were hospitalized between 15th January 2011 and 31st 
May 2011, in Neurological Department of Pitié-Salpétrière Hospital or Hôpital Universitaire 
of Limoges. Diagnosis of GBS was established according to criteria defined by Asbury et. al 
.[69]. Patients under the treatment of  immunomodulatory or immunosuppressive drugs in 3 
months prior to diagnosis of GBS, and those who were associated with other autoimmune 
disease and lymphoid disorders (lymphopenia <1000/mm3, lymphoma, or infection with 
HIV) were excluded from the study. Five patients with the mean age of 67.6 ± 4.2 years were 
included in the study who fulfiled the diagnostic criteria. Relevant ethical committee 
approval (84-2012-08, CHU Limoges) and the consent from patients were obtained. The 
average onset of the neurological diseases was 11.6 ± 2.8 days at the time of patient inclusion 
in the study. All the patients included in the study showed AIDP, which is classical form of 
GBS. 
Clinical evaluation 
Patients with GBS were examined prior to the IVIg treatment and 1 week, 2 weeks and 4-5 
weeks after the IVIg treatment, for their muscular weakness using Medical Research Council 
grading system (MRC), and for motor function disability based on modified Rankin scale 
(mRS). Briefly, the MRC sum score is a summation of the MRC grades (range, 0–5) given in 
full numbers for the muscle pairs in hands and legs and that of mRS assigns grades ranging 
 7 
from 0 (no symptoms at all) to 5 (severe disability, bedridden, incontinent, and requiring 
constant nursing care and attention) [70, 71].  
Sample preparation and analyses of cellular populations by flow cytometry 
Blood samples (40-50 mL in lithium heparin) were obtained by peripheral venous blood at 
prior to the start of the treatment (0 week) and 1, 2 and 4-5 weeks after the treatment of IVIg. 
All the analyses were performed within 24 h following blood collection.  
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque (1.077 g/ml) 
density centrifugation. PBMCs were then labelled with flurochrome conjugated antibodies to 
surface markers CD4 and then fixed and permeabilised using Foxp3 intracellular staining kit 
(eBioscience, France) according to the manufacturer’s instructions to determine the 
CD4+Foxp3+ Treg cells. 
For the intracellular detection of T cell cytokines (IFN-γ, TNF-α, IL-4, IL-17 and IL-22), 
PBMCs were suspended in X-VIVO 15 culture medium (Lonza, France) and stimulated using 
phorbol 12-myristate 13-acetate (at 50 ng/ml; PMA, Sigma, France) and ionomycin (at 500 
ng/ml, Sigma, France) at 37°C for 4 h, in the presence of GolgiStop (protein transport 
inhibitor; BD Biosciences, France). Different Th cell populations were identified by surface 
staining of CD4 and intracellular staining of T cell cytokines using Foxp3 staining kit 
(eBioscience). All flurochrome-conjugated antibodies were obtained from BD Biosciences, 
except for antibodies to IL-17A and Foxp3 (eBioscience). Around 50,000 cells/sample were 
acquired on flow cytometry (LSR II, BD Biosciences) using FACS DIVA™ and data were 
analysed using FlowJo software. 
 
Functional analysis of Treg cells by T cell suppression assay 
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Using the PBMCs, untouched CD4+ T cells were isolated by negative selection using the 
CD4+ T-cell isolation kit II (Miltenyi Biotec, France). Further, naïve (CD45RA+) and 
memory (CD45RA-) CD4+ T cells were separated using the CD45RA microbeads (Miltenyi 
Biotec) by positive selection. Finally, CD45RA- memory T cells were separated in to CD25+ 
and CD25- cells using CD25 microbeads (Miltenyi Biotec). CD4+CD45RA-CD25+ cells were 
used as Treg cells and total CD4+CD25- cells were used as Teff cells for the T cell suppression 
assay.  
Ninety-six-well U-bottom plates were coated with 1.5 μg/mL anti-CD3 mAb (R&D systems, 
France) for 2 h at 37°C. Plates were then rinsed once with serum-free RPMI-1640 medium. 
Tregs and Teff cells were co-cultured at different ratios (Tregs:Teff at 0:1, 1:4, 1:2, 1:1) in serum-
free X-VIVO 15 medium in the presence of soluble anti-CD28 mAb (1.0 μg/mL, R&D 
systems) for 4 days at 37°C. After 3 days, tritiated [3H ] thymidine was added and T cell were 
cultured for another 18 h. Subsequently, the cell culture plates were frozen at -20°C for 
further analysis of [3H] thymidine incorporation by liquid scintillation to assess the degree of 
proliferation of Teff cells and to determine the T-cell suppressive function of Treg cells. 
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Results 
Treatment with IVIg ameliorates the functional motor deficit in GBS patients 
All GBS patients examined are elderly individuals, with a mean age of 67.6 years. The 
clinical examination scores for MRC and mRS of GBS patients before (0 week) and after (1, 
2 and 4-5 weeks) IVIg treatment are depicted in the Fig 1. Notably, there was a wide 
variation in the degree of functional motor deficit prior to IVIg therapy among the GBS 
patients. Consistent with the previous studies [21, 47, 48], GBS patients treated with high 
dose IVIg (0.4 g/Kg body weight per day for 4 days) showed a clinical improvement as 
evidenced by the increase in MRC score and/or decrease in the modified Rankin scale. The 
clinical amelioration of GBS was observed as early as 1 week following initiation of IVIg 
therapy in the patients GBS-P1, -P2 and -P4, and from 2 weeks in GBS-P5 (Fig 1). However, 
no improvement was observed in GBS-P3 following IVIg treatment. Of note, GBS-P3 
showed mild form of disease and failed to respond to IVIg therapy. The maximal 
improvement was seen in patient 1, who had the most severe motor deficiency at the 
beginning. In summary, 4 out of 5 (80%) patients responded to the IVIg therapy with a 
considerable improvement in their motor functions (Fig 1). In fact, the efficacy of IVIg in the 
treatment of severe form of GBS is well established, but not the mild form of disease [20, 21, 
47]. This might explain the variations observed in the response to IVIg therapy within the 
cohort of GBS patients. 
IVIg decreases the circulating Th1 and Th17 cells in GBS patients 
After establishing the therapeutic efficacy of IVIg in GBS patients, we next investigated the 
cellular mechanisms mediating the clinical amelioration of disease. The present cohort of 
GBS patients showed the classical AIDP subtype of GBS, which is primarily caused by self-
reactive Teff cells. Since recent studies have indicated that Th1 and Th17 cells are associated 
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with the severity of disease in GBS patients and EAN models [23-26], we evaluated the 
frequencies of different Th cell subsets in the blood of GBS patients. 
Following the intracellular staining of PBMCs for T cell cytokines, such as IFN-γ, TNF-α, 
IL-4, IL-17 and IL-22, different Th cell subsets were identified within the CD4+ T cells, 
including Th1 (IFN-γ+), Th17 (IL-17+), Th22 (IL-22+) and Th2 (IL-4+) (Fig 2). Consistent 
with the previous reports [23-26], GBS patients showed increased frequencies of Teff cell 
subsets, such as Th1, Th17 and Th22, compared to the healthy donors (Fig 2a and b). TNF-α 
is a proinflammatory cytokine expressed mainly by inflammatory Th1 cells, but also Th17 
and Th22 cells. Notably, the frequency of CD4+ Th cells expressing TNF-α is also elevated in 
the blood of GBS patients compared to healthy donors (Fig 2b). However, the frequency of 
Th2 cells, which are the primary Teff cells implicated in allergic response, was similar to that 
of healthy donors (Fig 2c). 
Interestingly, there was a marked decrease in the frequencies of IFN-γ+, TNF-α+, IL-17+ and 
IL-22+ Th cells in the peripheral blood of GBS patients following IVIg therapy (Fig 2a and 
b). Despite the wide difference in the frequencies of Th cells before IVIg treatment among 
GBS patients, Teff cells were down-regulated to a similar levels following 4 weeks of IVIg 
therapy (except for IFN-γ+ Th cells). Further, the decline in the Teff cells was drastic in GBS-
P1, -P2 and P4, who also had relatively severe form of disease (Fig 1 and 2). Notably, GBS-
P3 and –P5 showed a moderate change in Th cells, which is consistent with their response to 
IVIg therapy (Fig 1 and 2). Despite a moderate changes in the frequencies of IL-4+ Th cells, 
IVIg therapy does not appear to alter Th2 cells in GBS patients. Taken together, these results 
suggest that IVIg treatment selectively down-regulates the pathogenic Teff cells involved in 
GBS. 
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IVIg therapy expands CD4+Foxp3+ Treg cells in GBS patients 
CD4+Foxp3+ Treg cells play a critical role in sustaining immune homeostasis. While 
deficiency of Treg cells is associated with autoimmune and inflammatory conditions, 
increased number of Treg cells can lead to resolution of immune-mediated pathologies, which 
is associated with suppression of effector immune cells [35, 36, 38-40, 72, 73]. Therefore, we 
next explored whether the inhibition of Teff cells by IVIg is associated with expansion of Treg 
cells in GBS patients. 
 Compared to healthy donors, peripheral blood of GBS patients had lower frequency of 
CD4+Foxp3+ Treg cells prior to IVIg therapy, supporting the significance of Treg cells in 
controlling autoimmune response (Fig 3a). Our recent report demonstrates that IVIg therapy  
leads to increase in the Treg cell frequency one-week following IVIg treatment in GBS 
patients P1, P2, P3 and P4 and was asociated with an increased circulating prostagladin E2 
[74]. In P4, the increase in Treg cell was marginal.  Here we followed the evolution of Treg 
cells up to 4-5 weeks post-IVIg infusion. We observed that GBS-P4 showed a delayed 
increase (2-week) in Treg cells and that of GBS-P5 failed to up-regulate Treg cells. By 4th 
week, Treg frequency returned to day-0 level in three patients. However, two patients  (P1 and 
P3) still showed high frequency of Treg cells even after 4 weeks. Furthermore, T cells 
expressing Helios were also increased following IVIg therapy (Fig 3b). Notably, the ratio of 
Teff to Treg cell frequencies (IFN-γ+:Foxp3+ and IL-17A+:Foxp3+) showed a marked 
reduction in GBS patients (except P5) following IVIg treatment (Fig 3c). These findings 
indicate that IVIg induces expansion of Foxp3+ Treg cells, which might be involved in 
suppression of Teff cells to achieve amelioration of clinical disease. 
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Treg cells expanded by IVIg are efficient in T-cell suppression 
Finally, we examined the inhibition of T cell proliferation by enriched  Treg cells to assess the 
functional status. Consistent with other autoimmune studies, Treg-enriched cells of GBS 
patients prior to IVIg treatment were defective in suppression of Teff cell proliferation, as 
compared to healthy donor (Fig 4). In contrast to Treg cell number-dependent reduction in Teff 
cell proliferation in healthy donor, Treg-enriched cells from GBS patients (GBS-P1: pre-IVIg) 
promoted Teff cell proliferation (Fig 4). Notably, following IVIg treatment, Treg-enriched cells 
from GBS patients showed cell number-dependent reduction in Teff cell proliferation (GBS-
P1: 1-week post-IVIg), similar to healthy donors (Fig 4).  These results suggest that IVIg 
therapy induces expansion of Treg cells with a restored T-cell suppressive function in GBS 
patients. 
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Discussion 
In the present study, we showed that beneficial effect of IVIg therapy in GBS patients with 
AIPD is characterised by selective decrease in the frequencies of pathogenic Th1 and Th17 
cells with a concomitant enrichment of Treg cells showing restored T-cell suppressive 
function. In contrast to the ability of B cells to promote Th2 polarization [75], treatment with 
natural antibodies (IVIg) did not alter the frequencies of Th2 cells in GBS patients. Our 
results thus indicate that the reciprocal regulation of Treg cells and Teff cell subsets is the 
cellular mechanism responsible for the therapeutic efficacy of IVIg in GBS and other 
autoimmune disease. Notably, similar to GBS, the restoration of imbalance between 
pathogenic T (Th1 and Th17) cells and Treg cells by IVIg therapy is also observed in patients 
with Kawasaki disease, and also recurrent pregnancy loss [76, 77]. As size of GBS patient 
cohort was small, the present study results need to be validated with investigation of large 
cohort of patients. 
Although the mechanistic events involved in the reciprocal regulation of Treg cells and 
pathogenic Th1 and Th17 by IVIg in GBS patients are unclear, the findings of recent studies 
of in vitro cell culture as well as experimental mouse models have provided novel insights 
into mode of action of IVIg in autoimmune and inflammatory diseases. Interestingly, IVIg is 
found to inhibit the differentiation of naive CD4 T cells into pathogenic T (Th1 and Th17) 
cells and decreases the expression of effector molecules such as IFN-γ, IL-17 and IL-22 in 
human T cell culture [63-65], and in experimental autoimmune encephalomyelitis (EAE) 
mouse model [66, 67]. Mechanistically, IVIg directly interact with T cells to inhibit 
differentiation and function, mainly by interfering with the pathways involved in the 
induction of lineage-specific transcription factor, RORC [63]. Concomitantly,  IVIg is shown 
to expand Treg cells, mainly by inducing proliferation of pre-existing natural Treg cells, rather 
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than de novo generation from naive T cells [54, 63]. Notably, the reciprocal regulation of Treg 
cells and Th17 in experimental autoimmune arthritis (EAA) mouse model by IVIg is found to 
be dependent on the up-regulation of IL-10 [78], which is an anti-inflammatory cytokine 
known to inhibit development and function of Th17 cells, but favour Treg cells [29, 30]. It is 
possible that direct interaction of IVIg with Th cell susbets in GBS patients mediates the 
reciprocal regulation. 
Of particular relevance, IVIg is also known to modulate the maturation, function and 
cytokine production of dendritic cells (DCs) [11, 79-84], which are the principal antigen 
presenting cells involved in development of Treg cells and Teff cell subsets during autoimmune 
response [85-87]. Consistent with this, interaction of IVIg with DCs is found to promote 
expansion of Treg cells through different mechanisms, such as induction of cyclooxygenase-2-
dependent prostaglandin E2 (PGE2) [88], Tregitopes[53, 89] and modulation of notch 
ligands[56, 88]. Interestingly, increased levels of PGE2 was observed in the peripheral blood 
of GBS patients following IVIg therapy [74]. Therefore, in addition to direct effect on T cells, 
IVIg-mediated modulation of DCs might be involved in regulation of Th cell subsets in IVIg-
treated GBS patients.  
The role of Fc-sialylation and Fcγ receptor IIb (FcγRIIB) in the anti-inflammatory effects of 
IVIg has been proposed [17]. It is hypothesised that α2,6-sialylated Fc fragments interact 
with dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin-positive 
(DC-SIGN+) innate cells to release IL-33, which in turn expands the IL-4-producing 
basophils to mediate the anti-inflammatory effects [90]. Interestingly, studies performed with 
F(ab’)2 and desialylated-IVIg have shown that both Fc fragment region of IVIg and FcγRIIB 
expression are dispensable for the expansion of Treg cells as well as suppression of 
pathogenic Th cells [63, 66, 67, 88], similar to IVIg-mediated modulation of human DCs [84, 
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88, 91] and experimental autoimmune mouse models [66, 67, 92]. Of relevance, IVIg 
treatment induced a significant increase in the plasma levels of IL-33 to a similar extent in 
GBS patients, irrespective of Th cell modulation and therapeutic outcome (data not shown). 
These results support the recent findings of lack of correlation between the plasma IL-33 
levels and the basophil number in autoimmune patients treated with IVIg [93]. Furthermore, 
basophils and sialylation of IVIg were not required for the therapeutic efficacy of IVIg in 
arthritis mouse models [94].  
Since IVIg is known to contain cytokine-specific antibodies [1], it is possible that treatment 
of GBS patients with IVIg results in neutralization of inflammatory cytokines, which can in 
turn favour Treg cell expansion, while inhibiting inflammatory Th1 and Th17 cell subsets 
[95]. In addition, IVIg can also directly interact with B cells to inhibit their activation 
proliferation and functions through induction of anergy and apoptosis [96-98]. These features 
of IVIg might be relevant in the axonal forms of GBS, which are mainly caused by antibodies 
to gangliosides [20, 21, 99]. Furthermore, IVIg is also found to target neutrophils to down-
regulate their activation and functions to exert anti-inflammatory mechanisms [100, 101], 
which may indirectly influence the development and function of Th cells.  In summary, 
multitude of cellular and molecular mechanisms might be involved in the reciprocal 
regulation of effector T (Th1 and Th17) cells and Treg cells by IVg therapy in GBS (Fig 5). 
Thus, IVIg exhibits the unique feature of pluripotency in order to achieve the therapeutic 
efficacy in diverse immune-mediated pathologies [102]. 
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Figure Legend 
Fig. 1 Changes in the clinical evaluation score of GBS patients over time following IVIg 
therapy Clinical examination of GBS patients was done before and after 1, 2 and 4-5 weeks 
of IVIg administration for assessing the muscular weakness by Medical Research council 
(MRC) sum score and the motor function disability by modified Rankin scale (mRS). 
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Fig. 2 Temporal changes in the frequency of circulating effector CD4+ Th cell subsets in 
GBS patients following IVIg therapy PBMCs from GBS patients were analysed by staining 
of surface CD4 and intracellular T cell cytokines. a-c The percentage of CD4+ Th cells 
expressing IFN-γ, IL-17A, TNF-α, IL-22 and IL-4 was determined by flow cytometry at 
different time-interval before and after IVIg treatment.   
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Fig. 3 Temporal changes in the frequency of circulating Foxp3+ CD4+ regulatory T 
(Treg) cell population in GBS patients following IVIg therapy PBMCs from GBS patients 
were analysed by staining of surface CD4 and intracellular Foxp3. a, b The percentage of 
CD4+ Th cells expressing Foxp3 and Helios was determined by flow cytometry at different 
time-interval before and after IVIg treatment. The Treg frequency of day zero and 1 week is 
from the previous report74. c The ratio of CD4+ Th cells expressing IFN-γ to that of Foxp3 
and IL-17A to that of Foxp3. 
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Fig. 4 T cell suppressive function of regulatory T (Treg) cell population is restored in 
GBS patients following IVIg therapy Treg –enriched cells and effector T (Teff) cells isolated 
from PBMCs of GBS patients were co-cultured in quadruplicates at different ratios (Tregs:Teff 
at 1:4, 1:2, 1:1) in serum-free X-VIVO 15 medium in the presence of plate-bound anti-CD3 
and soluble anti-CD28 mAb for 4 days at 37°C. T cell proliferation (upper panels) was 
determined by [3H] thymidine incorporation assay. Percentage change in proliferation of Teff 
cells in the presence of increasing number of Treg cells is presented. 
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Fig. 5 The proposed mechanisms involved in the reciprocal regulation of Th1/Th17 cells 
and Tregs cells by IVIg. Exposure of effector T (Teff) cells to IVIg results in inhibition of 
activation, differentiation and cytokine secretion. Parallel, interaction of Treg cells with IVIg 
or IVIg-modulated antigen presenting cells (APCs) leads to expansion and enhanced 
suppressive function of Treg cells. These IVIg-modulated Treg cells exhibit an increased 
expression of Foxp3 and Helios. IVIg-modulated Treg cells are efficient inhibitors of effector 
Teff cells. In addition to these direct effects, IVIg-mediated modulation of cytokine network 
as a result of altered cytokine production from APCs and neutralization of inflammatory 
cytokines can create a microenvironment favorable for Treg cell expansion, while inhibiting 
Teff cells.  
 
 
